PURPOSE: This study was designed to explore the value of carbohydrate antigen 72-4 (CA72-4) combined with carbohydrate antigen 15-3 (CA153) in diagnosing gynecologic malignancies. METHODS: 64 patients with ovarian cancer admitted to our hospital from February 2014 to February 2016 comprised the group A; 52 cases of cervical cancer were regarded as group B; 46 cases of endometrial cancer comprised the group C; and 150 cases of healthy women were considered as a control group. The CA72-4 and CA15.3 levels in serum of each group were detected, and receiver operating characteristics (ROC) curve was used to analyze the diagnostic value of CA72-4 and CA15.3 in ovarian, cervical, as well as in endometrial cancer. RESULTS: CA72-4 and CA15.3 increased dramatically in cancer patients (p<0.001). CA15.3 in group C was higher than in groups A and B (p<0.05). Joint diagnosis of the two had good sensitivity, specificity and area under the curve (AUC) for ovarian, cervical as well as for endometrial cancer (p<0.001). CA72-4 and CA15.3 were closely related to the occurrence of gynecologic malignancies (p<0.001). The results of follow-up revealed that CA72-4 had a higher value in predicting the death of ovarian cancer patients within 3 years, while CA15.3 had a better effect in predicting the death of ovarian and cervical cancer (p<0.05). CONCLUSION: CA72-4 and CA15.3 were dramatically higher in ovarian, cervical and endometrial cancer among gynecologic malignancies. Joint detection of the two had better diagnostic value for ovarian and cervical cancer.
PURPOSE: This study was designed to explore the value of carbohydrate antigen 72-4 (CA72-4) combined with carbohydrate antigen 15-3 (CA153) in diagnosing gynecologic malignancies. METHODS: 64 patients with ovarian cancer admitted to our hospital from February 2014 to February 2016 comprised the group A; 52 cases of cervical cancer were regarded as group B; 46 cases of endometrial cancer comprised the group C; and 150 cases of healthy women were considered as a control group. The CA72-4 and CA15.3 levels in serum of each group were detected, and receiver operating characteristics (ROC) curve was used to analyze the diagnostic value of CA72-4 and CA15.3 in ovarian, cervical, as well as in endometrial cancer. RESULTS: CA72-4 and CA15.3 increased dramatically in cancerpatients (p<0.001). CA15.3 in group C was higher than in groups A and B (p<0.05). Joint diagnosis of the two had good sensitivity, specificity and area under the curve (AUC) for ovarian, cervical as well as for endometrial cancer (p<0.001). CA72-4 and CA15.3 were closely related to the occurrence of gynecologic malignancies (p<0.001). The results of follow-up revealed that CA72-4 had a higher value in predicting the death of ovarian cancerpatients within 3 years, while CA15.3 had a better effect in predicting the death of ovarian and cervical cancer (p<0.05). CONCLUSION: CA72-4 and CA15.3 were dramatically higher in ovarian, cervical and endometrial cancer among gynecologic malignancies. Joint detection of the two had better diagnostic value for ovarian and cervical cancer.